Alcohol linked to metabolic risks at lower amounts without obesity
Daily drinking was linked to multiple metabolic problems at 20 grams of alcohol or more without obesity, versus 60 grams or more with obesity.
Our read
Populations- Studied:
- Cross-sectional study of 36,006 individuals aged 40-64 years, against obese individuals
- What changed:
- Risk of multiple metabolic syndrome components was higher in non-obese individuals than in obese individuals, even at lower drinking amounts
- The catch:
- Participants reported their own drinking rather than having alcohol intake objectively measured
- Stake:
- Tokio Marine dR funded the study.
- In the record:
- The 841st paper on alcohol with results in people; 2,880 on record in all.
Editor of record: Boris Djordjevic · AgingResearch.News
Researchers conducted a cross-sectional study of 36,006 men and women aged 40–64 enrolled in five health insurance associations affiliated with Japanese manufacturing companies. They analyzed 2015 health-checkup, questionnaire and insurance data. The outcome was having at least two metabolic syndrome components: high blood pressure, high blood sugar or abnormal blood fat levels.
Among people without obesity, daily drinking of at least 20 grams of pure alcohol, or occasional drinking of at least 40 grams, was associated with multiple components. Among people with obesity, daily drinking of at least 60 grams showed this association. Amounts referred to drinking days. Daily drinking below 20 grams was associated with a lower prevalence of multiple components in both groups. Occasional drinking below 20 grams was also associated with a lower prevalence among people with obesity.
Why it matters
The findings bear on whom to support in reducing alcohol consumption for metabolic health in middle age. The authors emphasized including people without obesity.
Caveats
The cross-sectional design could not establish cause and effect, and participants reported their own drinking. Results may not apply to other ages or people with excluded conditions, including stroke, heart disease and chronic kidney disease.
The paper
University of Tsukuba
Neuropsychopharmacology Reports, Mar 16, 2026, Open access
Comments
Be the first to comment.